Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 1042 • 2015 ACR/ARHP Annual Meeting
Pragmatic Multicenter Open-Label Randomized Controlled Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients in Remission or Stable Low Disease Activity in the Netherlands
Marjan Ghiti Moghadam¹, Harald E. Vonkeman², Peter M. ten Klooster³, Janneke Tekstra⁴, Dirkjan van Schaardenburg⁵, Mirian Starmans-kool^6,7, Elisabeth Brouwer⁸, Reinhard Bos⁹, Willem F. Lems¹⁰, Edgar Colin¹¹, Cornelia F. Allaart¹², Inger L. Meek¹³, Robert B.M. Landewé¹⁴, Hein J. Bernelot Moens¹⁵, Piet van Riel¹³, Mart A.F.J. van de Laar¹⁶, Tim Jansen¹⁷ and on behalf of the Dutch National POET Collaboration., ¹rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ²Ariensplein 1, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³Pcgr, University of Twente, Enschede, Netherlands, ⁴Dept. Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Jan van Breemen Research Institute, Amsterdam, Netherlands, ⁶Rheumatology, Orbis Medical Center, Geleen-Sittard, Netherlands, ⁷Rheumatology, Atrium Medical center, Heerlen, Netherlands, ⁸Rheumatology, University Medical center Groningen, Groningen, Netherlands, ⁹Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ¹⁰Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ¹¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ¹²Department of Rheumatology, Leiden Universitary Medical Center, Leiden, Netherlands, ¹³Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁴Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ¹⁵rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands, ¹⁶Rheumatology, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ¹⁷VieCuri Medical Center, Venlo, Netherlands
Background/Purpose: TNF-inhibitors (TNFi) are effective treatments of rheumatoid arthritis (RA). It is not clear if patients in remission or stable low disease activity need to…
Abstract Number: 620 • 2015 ACR/ARHP Annual Meeting
Evaluation of Patients from the Non-Biologic Arms of Inflammatory Arthritis Clinical Trials Identifies Several Predictors of Remission, As Well As, Distinct Responder Subgroups
Brian Tom¹ and Deborah P.M. Symmons², ¹Biostatistics Unit, Medical Research Council, Cambridge, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom
Background/Purpose: The RA-MAP consortium is a UK flagship industry-academic partnership investigating clinical and biological predictors of disease outcome in patients with rheumatoid arthritis (RA). Methods:…
Abstract Number: 563 • 2015 ACR/ARHP Annual Meeting
Abatacept Plus Methotrexate Can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis
Paul Emery¹, G Burmester², VP Bykerk³, B Combe⁴, Daniel E. Furst⁵, M Maldonado⁶ and T. W. J. Huizinga⁷, ¹University of Leeds, Leeds, United Kingdom, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, New York, NY, ⁴Service d’Immuno-Rheumatologie, Montpellier, France, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Assessing Very Early Rheumatoid arthritis Treatment (AVERT) was a Phase IIIb, randomized, active-controlled study to evaluate the efficacy and safety of abatacept (ABA) treatment…
Abstract Number: 511 • 2015 ACR/ARHP Annual Meeting
Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
KAZUYUKI YOSHIZAKI, Organic Fine Chemicals, The Institute of Scientific and Industrial Research, Osaka University, Suita, Japan
Background/Purpose: In clinical practice in rheumatoid arthritis (RA), it has been noted that each anti-rheumatic therapy delivers a different outcome for individual RA patients and…
Abstract Number: 465 • 2015 ACR/ARHP Annual Meeting
MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort
Mami Tamai¹, Yoshikazu Nakashima¹, Kazuhiko Arima², Junko Kita¹, Masataka Umeda¹, Shoichi Fukui¹, Ayako Nishino¹, Takahisa Suzuki¹, Yoshiro Horai¹, Akitomo Okada³, Tomohiro Koga¹, Shin-ya Kawashiri^1,2, Naoki Iwamoto¹, Kunihiro Ichinose¹, Satoshi Yamasaki⁴, Hideki Nakamura¹, Tomoki Origuchi⁵, Kiyoshi Aoyagi², Masataka Uetani⁶, Katsumi Eguchi⁷ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Public Health, Nagasaki University, Nagasaki, Japan, ³Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁴Hiroshima University, Hiroshima, Japan, ⁵Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁶Department of Radiology and Radiation Research, Nagasaki University, Nagasaki, Japan, ⁷Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan
Background/Purpose: Given the improved detection of joint injury by MRI than by clinical examination, EULAR recommendations for the use of imaging of the joints in…
Abstract Number: 448 • 2015 ACR/ARHP Annual Meeting
A Majority of Early Rheumatoid Arthritis (ERA) Patients Reach Remission By 6 Months in Usual Rheumatology Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen³, Timo Yli-Kerttula⁴, Päivi Ekman⁵, Laura Pirilä⁶, Markku Mali⁷, Laura Kuusela⁷, Maija Puurtinen-Vilkki⁷, Saara Kortelainen⁸, Johanna Paltta⁷, Kirsi Taimen⁷, Heidi Mäkinen⁹, Pia Isomäki⁹, Terhi Uotila⁹, Markku J. Kauppi¹⁰, Kari Laiho¹¹, Satu Nyrhinen¹¹, Tuulikki Sokka-Isler¹ and FIN-ERA study group, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁴Sairaalantie 3, Central Hospital of Satakunta, Pori, Finland, ⁵Central Hospital of Satakunta, Pori, Finland, ⁶Tyks, P.O. Box 52, Turku University Central Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Alvar Aallontie 275, Turku University Central Hospital, Turku, Finland, ⁹Tampere University Hospital, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Finnish national combination treatment trials have demonstrated excellent outcomes in patients with ERA including 90% of patients reaching DAS28 remission at 6 months. Whether…
Abstract Number: 443 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register
Pongthorn Narongroeknawin¹, Wanruchada Katchamart², Parawee Suwannalai³, Nuntana Kasitanon⁴, Tasanee Kitumnuaypong⁵, Ajanee Mahakkanukrauh⁶ and Boonjing Siripaitoon⁷, ¹Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, ²Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj hospital, Mahidol University, Bangkok, Thailand, ³Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁵Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital, Bangkok, Thailand, ⁶Division of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, ⁷Division of Rheumatology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
Background/Purpose: To evaluate long-term efficacy and safety of biological disease modifying antirheumatic drug (bDMARD) in real-life practice and identify risk factors related to remission and drug discontinuation…
Abstract Number: 440 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Rheumatoid Arthritis Patients Achieving HAQ Remission with 6 Months of Biologic Treatment
Yusuke Miwa¹, Ryo Takahashi¹, Airi Maeoka¹, Shinichiro Nishimi¹, Nao Oguro¹, Sho Ishii¹, Mika Kobuna¹, Takahiro Tokunaga¹, Masayu Umemura¹, Tsuyoshi Kasama¹, Katsunori Inagaki² and Yoichi Toyoshima³, ¹Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ²Department of Orthopedics, Showa University School of Med, Tokyo, Japan, ³Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Biologic agents are highly effective for rheumatoid arthritis (RA); however, not all cases achieve health assessment questionnaire (HAQ) remission. Although previous studies have reported…
Abstract Number: 3187 • 2015 ACR/ARHP Annual Meeting
Predictors of Disease Relapse and Recapture of Remission Following Relapse in an Ontario Rheumatoid Arthritis Population
Bindee Kuriya¹, Xiuying Li², George A. Tomlinson³, Edward C. Keystone⁴, Claire Bombardier² and OBRI Investigators, ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: The timing and severity of relapse and likelihood of “recapturing” remission following a relapse in RA is not well known. We aimed to describe…
Abstract Number: 434 • 2015 ACR/ARHP Annual Meeting
Duration of Remission By Currently Available Criteria Can Predict Physical Functioning, but Not Radiological Progression in Early Rheumatoid Arthritis Patients
Nicole P.C. Konijn¹, Lilian H.D. van Tuyl¹, Maarten Boers^1,2, D den Uyl¹, M.M. ter Wee¹, P.J.S.M. Kerstens^3,4, Alexandre E. Voskuyl⁵, Michael T. Nurmohamed^1,3, Dirkjan van Schaardenburg^3,6 and Willem F. Lems^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands, ²Epidemiology & Biostatistics, VU University medical center, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ⁴Rheumatology, Westfriesgasthuis, Hoorn, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, ⁶Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Several sets of remission criteria have been developed. The ACR/EULAR criteria were validated against their potential to predict prognosis of rheumatoid arthritis (RA) [1].…
Abstract Number: 3182 • 2015 ACR/ARHP Annual Meeting
High Body Mass Index Negatively Impacts Time to Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from a Multicenter Early Arthritis Cohort Study
Elizabeth Schulman¹, Kathleen Andersen², Meng Zhang³, Susan M. Goodman⁴, Daming Lin⁵, Gilles Boire⁶, Boulos Haraoui⁷, Carol Hitchon⁸, Shahin Jamal⁹, Edward C. Keystone¹⁰, Janet E. Pope¹¹, Diane Tin¹², Carter Thorne¹³, VP Bykerk² and CATCH Investigators, ¹Rheumatology, Hospital for Special Surgey, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ⁷Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Vancouver Coastal Health, Vancouver, BC, Canada, ¹⁰Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹¹University of Western Ontario, London, ON, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: High BMI has been associated with worse disease severity and lower rates of sustained remission (susREM) in early rheumatoid arthritis (ERA). In this study,…
Abstract Number: 3183 • 2015 ACR/ARHP Annual Meeting
The Clinical and Economic Costs of Not Achieving Remission in Rheumatoid Arthritis
Jeffrey R. Curtis¹, Lang Chen^1,2, Meredith Kilgore³, Huifeng Yun⁴ and Jeffrey D. Greenberg⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Bimingham, Birmingham, AL, ³Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, ⁴Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Corrona, LLC, Southborough, MA
Background/Purpose: Treat to target guidelines recommend achieving a state of remission or low disease activity for rheumatoid arthritis (RA) patients. However, the benefit of lower…
Abstract Number: 2654 • 2015 ACR/ARHP Annual Meeting
The Influence of Patient Reported Morning Stiffness on Patient Global Assessment in Rheumatoid Arthritis Patients Not Achieving ACR/EULAR Boolean Remission in a Large US Registry
Dimitrios A. Pappas^1,2, Robert J. Holt³, Ying Shan⁴, Jeffrey D. Kent⁵, John T. Nguyen⁴, Joel M. Kremer⁶ and Jeffrey D. Greenberg^2,7, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³University of Illinois - Chicago, Chicago, IL, ⁴Corrona, LLC., Southborough, MA, ⁵Horizon Pharma USA, Inc., Deerfield, IL, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: The ACR/EULAR Boolean definition of remission is expected to be used as an outcome measure in randomized clinical trials for rheumatoid arthritis (RA). Boolean…
Abstract Number: 2652 • 2015 ACR/ARHP Annual Meeting
Power Doppler Ultrasound Features in Rheumatoid Arthritis Patients in Clinical Remission: Reclassifying Disease Activity?
Facundo Vergara¹, Santiago Ruta¹, Maria de los Angeles Gallardo¹, Emmanuel Bertiller², Josefina Marin¹, Javier Rosa³, Ricardo Garcia-Monaco⁴ and Enrique R. Soriano⁵, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ³Rheumatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Many studies have shown disparity between clinical and ultrasound (US) findings in rheumatoid arthritis (RA). US appears to detect subclinical synovitis in patients in…
Abstract Number: 2028 • 2014 ACR/ARHP Annual Meeting
Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The Espoir Cohort
Thomas Krams¹, Adeline Ruyssen-Witrand², Delphine Nigon¹, Bruno Fautrel^3,4,5, Francis Berenbaum^6,7, Alain G. Cantagrel⁸ and Arnaud Constantin⁹, ¹Rhumatologie, Purpan University Hospital, Toulouse, France, ²Rheumatology, Purpan University Hospital, Toulouse, France, ³Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁴Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁵Rheumatology, Pitie Salpetriere Hospital, Paris, France, ⁶Service de Rhumatologie, Saint-Antoine Hospital, Paris, France, ⁷INSERM - UMR S 938, Paris, France, ⁸Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁹Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease with peak incidence in the fourth and fifth decades of age. To investigate whether age at disease…